Literature DB >> 11318767

A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects.

N Andersson1, A Källén, L Thorsson.   

Abstract

AIMS: To investigate the effect on the hypothalamo-pituitary-adrenal (HPA) axis of treatment with budesonide, 400 microg once daily, morning or evening, or 200 microg twice daily, and 800 microg twice daily via Turbuhaler in a randomized, placebo-controlled, double-blind, double-dummy crossover study.
METHODS: Healthy men received budesonide, 400 microg in the morning (08.00-09.00 h) or evening (20.00-21.00 h), budesonide, 200 microg twice daily, 800 microg twice daily, and placebo twice daily, for 1 week each. Plasma and urine samples were obtained over 24 h on day 7 for cortisol determination. Twenty-five subjects completed all treatments, and 27 were included in the analysis.
RESULTS: The 24 h plasma cortisol concentrations vs placebo (95% CI) were 98% (89, 108) for 400 microg in the morning, 92% (83, 100) for 400 microg in the evening, 95% (86, 104) for 200 microg twice daily, and 76% (70, 84) for 800 microg twice daily.
CONCLUSIONS: Budesonide at a dose of 400 microg day-1 via Turbuhaler had no statistically significant effect on 24 h cortisol production, irrespective of whether treatment is given once or twice daily, whereas a dose of 800 microg twice daily resulted in a statistically significant suppression vs placebo. Neither could a significant difference be found between morning and evening dosing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318767      PMCID: PMC2014452          DOI: 10.1046/j.1365-2125.2001.01353.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  A randomized controlled assessment of the systemic activity of budesonide when given once or twice daily via Turbuhaler.

Authors:  L Thorsson; A Källén
Journal:  Eur J Clin Pharmacol       Date:  2000-06       Impact factor: 2.953

2.  A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide.

Authors:  M Mann; O Eliasson; K Patel; R L ZuWallack
Journal:  Chest       Date:  1992-02       Impact factor: 9.410

3.  Diurnal cortisol secretion during therapy with inhaled beclomethasone dipropionate in children with asthma.

Authors:  E Tabachnik; Z Zadik
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

4.  Initial loading (400 micrograms twice daily) versus static (400 micrograms nocte) dose budesonide for asthma management. PLAN Research Group.

Authors:  L M Campbell; T N Gooding; W R Aitchison; N Smith; J A Powell
Journal:  Int J Clin Pract       Date:  1998-09       Impact factor: 2.503

5.  Single dose dexamethasone in treatment of congenital adrenocortical hyperplasia.

Authors:  A Hayek; J D Crawford; H H Bode
Journal:  Metabolism       Date:  1971-09       Impact factor: 8.694

6.  Assessment of the systemic effects of inhaled glucocorticosteroids: the influence of blood sampling technique and frequency on plasma cortisol and leucocytes.

Authors:  B H Jennings; K E Andersson; S A Johansson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals.

Authors:  A Reinberg; M H Smolensky; G E D'Alonzo; J P McGovern
Journal:  J Asthma       Date:  1988       Impact factor: 2.515

Review 8.  Corticosteroid inhibition of ACTH secretion.

Authors:  M E Keller-Wood; M F Dallman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

9.  The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone.

Authors:  R Schlaghecke; E Kornely; R T Santen; P Ridderskamp
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

10.  Compliance with inhaled therapy and morbidity from asthma.

Authors:  C R Horn; T J Clark; G M Cochrane
Journal:  Respir Med       Date:  1990-01       Impact factor: 3.415

View more
  1 in total

1.  Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial.

Authors:  Ashley Woodcock; Eric D Bateman; William W Busse; Jan Lötvall; Neil G Snowise; Richard Forth; Loretta Jacques; Brett Haumann; Eugene R Bleecker
Journal:  Respir Res       Date:  2011-10-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.